Bruce Jackson, MD
Cardiovascular Disease · Redondo Beach, CANPI 1609883438
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,228, 5.8 times the $211 reported in 2019.
Across 179 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$684
- E.r. Squibb & Sons, L.L.C.$529
- Novartis$270
- Johnson & Johnson$249
- Pfizer$190
- Scpharmaceuticals Inc.$164
- plus $1K from 18 others
Across 17 payments — averaging $2390.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$20K
- Sanofi US Services Inc.$19K
- Boehringer Ingelheim$2K
What the payments were for
- Food & beverage$3,130100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $684 |
| E.r. Squibb & Sons, L.L.C. | 61 | $529 |
| Novartis | 13 | $270 |
| Johnson & Johnson | 13 | $249 |
| Pfizer | 10 | $190 |
| Scpharmaceuticals Inc. | 7 | $164 |
| Boehringer Ingelheim | 5 | $146 |
| Merck | 5 | $114 |
| Boston Scientific | 4 | $89 |
| Abiomed | 3 | $80 |
| Bridgebio Pharma, Inc. | 2 | $74 |
| GE HealthCare | 2 | $67 |
| Amgen | 4 | $66 |
| AstraZeneca | 3 | $65 |
| Lantheus Medical Imaging, Inc. | 3 | $64 |
| Bayer | 2 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Ionis Pharmaceuticals, Inc. | 1 | $31 |
| GSK | 2 | $29 |
| AbbVie | 1 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| Philips North America LLC | 1 | $20 |
| Abbott | 1 | $20 |
How this compares
$3,139 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 560 | $609,605 |
| XareltoRivaroxaban | 114 | $128,856 |
| EntrestoSacubitril/Valsartan | 123 | $121,312 |
| JardianceEmpagliflozin | 40 | $40,889 |
| Praluent PenAlirocumab | 44 | $34,940 |
| BrilintaTicagrelor | 36 | $32,590 |
| FarxigaDapagliflozin Propanediol | 26 | $29,059 |
| Repatha SureclickEvolocumab | 22 | $20,045 |
| Repatha SyringeEvolocumab | 17 | $19,698 |
| MultaqDronedarone Hcl | 11 | $15,067 |
| Metoprolol Succinate | 563 | $9,320 |
| Rosuvastatin Calcium | 575 | $7,760 |
| Losartan Potassium | 458 | $5,826 |
| BenicarOlmesartan Medoxomil | 13 | $5,368 |
| Ezetimibe | 176 | $4,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $190 | $609,605560 claims |
| Johnson & JohnsonXarelto | $249 | $128,856114 claims |
| NovartisEntresto | $270 | $121,312123 claims |
| AstraZenecaBrilinta, Farxiga | $65 | $61,64962 claims |
| Boehringer IngelheimJardiance | $146 | $40,88940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Redondo Beach
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.